Ascendia

  MARKET NEWS

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
Amphista Therapeutics Nominates Orally Available Targeted Glue Degrader as its First Clinical Development Candidate
Owen Mumford Launches EcoSafe Safety Syringe Platform - Smarter for Budgets & Kinder to the Planet
Tagworks Pharmaceuticals Announces CTA Authorization & Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors
Quotient Sciences & Biorasi Partner to Accelerate Early Phase Clinical Trials to Patient Proof-of-Concept
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
Roquette Debuts its Next Chapter at CPHI 2025 Following Qualicaps & IFF Pharma Solutions Acquisitions
Traws Pharma Doses First Patient With Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Ensera Launches as New Brand Identity for SteriPack
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation

  EXPERT CONTENT & RESOURCES

How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?

How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?

Low bioavailability due to poor API solubility is one of the major challenges to be overcome when developing oral dosage form drug products. An effective way of addressing this problem is to transform low solubility APIs into amorphous solid dispersions (ASDs) and can often be achieved via hot melt extrusion (HME).

Nitrosamine Risk Assessment and Mitigation in Pharmaceutical Products

Nitrosamine Risk Assessment and Mitigation in Pharmaceutical Products

This paper explores practical approaches for identifying and mitigating nitrosamine risks in drug products, integrating emerging tools such as predictive machine learning, advanced nitrite testing methodologies, and strategic excipient sourcing.

CAPMUL GDO (Glycerol Dioleate) is a Versatile Excipient for Pharmaceutical Formulations

CAPMUL GDO (Glycerol Dioleate) is a Versatile Excipient for Pharmaceutical Formulations

ABITEC is excited to present its latest excipient, CAPMUL GDO, Glycerol Dioleate.  CAPMUL GDO is a high-purity, highly versatile functional lipid

  FEATURED EDITORIAL

  COMPANY PROFILE

With trusted scientific insight brought to every program, Quotient Sciences is a drug development & manufacturing accelerator helping clients bring molecules to cures, fast. With drug product development, manufacturing, and clinical testing facilities located in both the US and the UK, Quotient Sciences has worked with customers as a trusted CRDMO partner for over 35 years. Our approach to program design and delivery saves time in getting new therapies to market, without compromising quality and control of the product, data, and processes along the way. Click here for more.

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules

ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules

In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.

vytal webinar

WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future

In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

 

The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …

WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine

WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine

By: Dr. Jens Morgenthaler, General Manager and Dr. Matthias Rischer, Head of Innovation, Losan Pharma GmbH

 Introduction

The successful formulation of small molecules is still one of the important challenges of today, especially if these drugs belong to the BioClassificationSystem …

WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing

WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing

SGS, the world’s leading testing, inspection and certification company, recently announced the release of a new white paper, 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing.

Targeted at researchers, toxicologists and formulation scientists in the clinical and dermatological …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 22 – Transdermal/Topical Delivery
October 29 – Formulation Development